Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid

Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by social interaction deficits and repetitive/stereotyped behaviors. Its prevalence is increasing, affecting one in 36 children in the United States. The valproic acid (VPA) induced animal model of ASD is a re...

Full description

Bibliographic Details
Main Authors: Gustavo Brum Schwingel, Mellanie Fontes-Dutra, Bárbara Ramos, Rudimar Riesgo, Victorio Bambini-Junior, Carmem Gottfried
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:IBRO Neuroscience Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2667242123022650
_version_ 1797383699118948352
author Gustavo Brum Schwingel
Mellanie Fontes-Dutra
Bárbara Ramos
Rudimar Riesgo
Victorio Bambini-Junior
Carmem Gottfried
author_facet Gustavo Brum Schwingel
Mellanie Fontes-Dutra
Bárbara Ramos
Rudimar Riesgo
Victorio Bambini-Junior
Carmem Gottfried
author_sort Gustavo Brum Schwingel
collection DOAJ
description Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by social interaction deficits and repetitive/stereotyped behaviors. Its prevalence is increasing, affecting one in 36 children in the United States. The valproic acid (VPA) induced animal model of ASD is a reliable method for investigating cellular, molecular, and behavioral aspects related to the disorder. Trans-Resveratrol (RSV), a polyphenol with anti-inflammatory and antioxidant effects studied in various diseases, has recently demonstrated the ability to prevent cellular, molecular, sensory, and social deficits in the VPA model. In this study, we examined the effects of prenatal exposure to VPA and the potential preventive effects of RSV on the offspring. Method: We monitored gestational weight from embryonic day 6.5 until 18.5 and assessed the onset of developmental milestones and morphometric parameters in litters. The generalized estimating equations (GEE) were used to analyze longitudinal data. Results: Exposure to VPA during rat pregnancy resulted in abnormal weight gain fold-changes on embryonic days 13.5 and 18.5, followed by fewer animals per litter. Additionally, we discovered a positive correlation between weight variation during E15.5-E18.5 and the number of rat pups in the VPA group. Conclusion: VPA exposure led to slight length deficiencies and delays in the onset of developmental milestones. Interestingly, the prenatal RSV treatment not only prevented most of these delays but also led to the early onset of certain milestones and improved morphometric characteristics in the offspring. In summary, our findings suggest that RSV may have potential as a therapeutic intervention to protect against the negative effects of prenatal VPA exposure, highlighting its importance in future studies of prenatal neurodevelopmental disorders.
first_indexed 2024-03-08T21:23:47Z
format Article
id doaj.art-f8ef20eacdfc4dab998007fab176ac26
institution Directory Open Access Journal
issn 2667-2421
language English
last_indexed 2024-03-08T21:23:47Z
publishDate 2023-12-01
publisher Elsevier
record_format Article
series IBRO Neuroscience Reports
spelling doaj.art-f8ef20eacdfc4dab998007fab176ac262023-12-21T07:38:34ZengElsevierIBRO Neuroscience Reports2667-24212023-12-0115242251Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acidGustavo Brum Schwingel0Mellanie Fontes-Dutra1Bárbara Ramos2Rudimar Riesgo3Victorio Bambini-Junior4Carmem Gottfried5Translational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Brazil; Autism Wellbeing and Research Development (AWARD) Initiative, BR-UK-CA, Brazil; Corresponding authors at: Translational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, BrazilTranslational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Brazil; Autism Wellbeing and Research Development (AWARD) Initiative, BR-UK-CA, BrazilTranslational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, BrazilTranslational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Brazil; Autism Wellbeing and Research Development (AWARD) Initiative, BR-UK-CA, Brazil; Child Neurology Unit, Hospital de Clínicas de Porto Alegre (HCPA), BrazilNational Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Brazil; Autism Wellbeing and Research Development (AWARD) Initiative, BR-UK-CA, Brazil; Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, United KingdomTranslational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Department of Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; National Institute of Science and Technology on Neuroimmunomodulation (INCT-NIM), Brazil; Autism Wellbeing and Research Development (AWARD) Initiative, BR-UK-CA, Brazil; Corresponding authors at: Translational Research Group in Autism Spectrum Disorders-GETTEA, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, BrazilBackground: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition characterized by social interaction deficits and repetitive/stereotyped behaviors. Its prevalence is increasing, affecting one in 36 children in the United States. The valproic acid (VPA) induced animal model of ASD is a reliable method for investigating cellular, molecular, and behavioral aspects related to the disorder. Trans-Resveratrol (RSV), a polyphenol with anti-inflammatory and antioxidant effects studied in various diseases, has recently demonstrated the ability to prevent cellular, molecular, sensory, and social deficits in the VPA model. In this study, we examined the effects of prenatal exposure to VPA and the potential preventive effects of RSV on the offspring. Method: We monitored gestational weight from embryonic day 6.5 until 18.5 and assessed the onset of developmental milestones and morphometric parameters in litters. The generalized estimating equations (GEE) were used to analyze longitudinal data. Results: Exposure to VPA during rat pregnancy resulted in abnormal weight gain fold-changes on embryonic days 13.5 and 18.5, followed by fewer animals per litter. Additionally, we discovered a positive correlation between weight variation during E15.5-E18.5 and the number of rat pups in the VPA group. Conclusion: VPA exposure led to slight length deficiencies and delays in the onset of developmental milestones. Interestingly, the prenatal RSV treatment not only prevented most of these delays but also led to the early onset of certain milestones and improved morphometric characteristics in the offspring. In summary, our findings suggest that RSV may have potential as a therapeutic intervention to protect against the negative effects of prenatal VPA exposure, highlighting its importance in future studies of prenatal neurodevelopmental disorders.http://www.sciencedirect.com/science/article/pii/S2667242123022650AutismVPAResveratrolMilestonesAnimal modelMorphometric parameters
spellingShingle Gustavo Brum Schwingel
Mellanie Fontes-Dutra
Bárbara Ramos
Rudimar Riesgo
Victorio Bambini-Junior
Carmem Gottfried
Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid
IBRO Neuroscience Reports
Autism
VPA
Resveratrol
Milestones
Animal model
Morphometric parameters
title Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid
title_full Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid
title_fullStr Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid
title_full_unstemmed Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid
title_short Preventive effects of resveratrol against early-life impairments in the animal model of autism induced by valproic acid
title_sort preventive effects of resveratrol against early life impairments in the animal model of autism induced by valproic acid
topic Autism
VPA
Resveratrol
Milestones
Animal model
Morphometric parameters
url http://www.sciencedirect.com/science/article/pii/S2667242123022650
work_keys_str_mv AT gustavobrumschwingel preventiveeffectsofresveratrolagainstearlylifeimpairmentsintheanimalmodelofautisminducedbyvalproicacid
AT mellaniefontesdutra preventiveeffectsofresveratrolagainstearlylifeimpairmentsintheanimalmodelofautisminducedbyvalproicacid
AT barbararamos preventiveeffectsofresveratrolagainstearlylifeimpairmentsintheanimalmodelofautisminducedbyvalproicacid
AT rudimarriesgo preventiveeffectsofresveratrolagainstearlylifeimpairmentsintheanimalmodelofautisminducedbyvalproicacid
AT victoriobambinijunior preventiveeffectsofresveratrolagainstearlylifeimpairmentsintheanimalmodelofautisminducedbyvalproicacid
AT carmemgottfried preventiveeffectsofresveratrolagainstearlylifeimpairmentsintheanimalmodelofautisminducedbyvalproicacid